GoodRx Unveils Lowest Discounted Cash Price for neffy® (Epinephrine Nasal Spray) at Retail Pharmacies

GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., has announced a collaboration with ARS Pharmaceuticals, Inc. to provide the lowest discounted cash price for neffy®, available at retail pharmacies. Starting this week, consumers prescribed neffy can purchase a pack of two single-use devices for $199 at over 70,000 pharmacies nationwide through GoodRx.

“We’re dedicated to offering neffy at a lower price to help eliminate longstanding barriers in anaphylaxis treatment, providing an option for millions, particularly children and adults who need to carry epinephrine for timely and effective treatment,” said Dorothy Gemmell, Chief Commercial Officer at GoodRx.

Approved by the Food and Drug Administration in August, neffy is the first needle-free treatment for Type I allergic reactions, including anaphylaxis. It provides an innovative alternative to auto-injectors by delivering epinephrine nasally, eliminating the need for needle injections.

Allergies affect over 100 million Americans each year, with more than 50 million experiencing allergic reactions. Anaphylaxis can cause severe symptoms such as difficulty breathing, rapid heartbeat, and loss of consciousness, often occurring within moments of exposure to an allergen. neffy enhances accessibility and affordability for those affected by severe allergies.

“We’re excited about neffy’s FDA approval, allowing individuals with severe allergies to avoid the anxiety associated with needle injections. Our partnership with GoodRx helps ensure that this innovative option is accessible at retail pharmacies, supported by patient programs for affordability,” said Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharmaceuticals.

GoodRx collaborates with nearly 150 brands in the pharmaceutical and medical device sectors to connect savings and patient support programs to consumers, enhancing access to cost-effective treatments. The company also recently launched affordability programs with Boehringer Ingelheim for its Humira® biosimilar and Sanofi for insulin Lantus.

Consumers can learn more about the savings on neffy at www.goodrx.com/neffy.

For important safety information, visit neffy.com and refer to the full Patient Information.

About GoodRx

GoodRx is the leading prescription savings platform in the U.S., trusted by over 25 million consumers and 750,000 healthcare professionals annually. It offers access to savings for generic and brand-name medications at more than 70,000 pharmacies nationwide, alongside comprehensive healthcare research and information. Since its inception in 2011, GoodRx has helped consumers save over $75 billion on prescriptions.

For investor-related information, visit GoodRx’s investor relations website.

Forward-Looking Statements

This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. Statements regarding anticipated consumer savings, partnership benefits, and future plans are forward-looking and involve risks and uncertainties that may lead to different actual results than those expressed or implied. GoodRx disclaims any obligation to update forward-looking statements, even if circumstances change.

Source link

Share your love

Newsletter Updates

Enter your email address below and subscribe to our newsletter